V

Victoria Clinical Research Group | Victoria, TX

Research site

Location

2700 Citizens Plaza Suite 206, Victoria, Texas, United States of America

Site insights

Top conditions

Top treatments

LY3502970

Dulaglutide

Orforglipron

Rimegepant

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

4 of 6 total trials

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main o...

Active, not recruiting

Epstein-Barr Virus Infection

Biological: mRNA-1189

Biological: Placebo

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes (ACHIEVE-PEDS)

This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 t...

Not yet enrolling

Diabetes Mellitus, Type 2

Drug: Orforglipron

Drug: Dulaglutide

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and ado...

Enrolling

Migraine

Drug: Placebo

Drug: Rimegepant

Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents

The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germ...

Enrolling

Pneumococcal Disease

Biological: PG4

Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms